June 26 (Reuters) - The U.S. Food and Drug Administration on Wednesday issued guidance to drugmakers on steps to improve diversity in clinical trials.
The draft guidance requires companies and researchers conducting trials to lay out their goals for study enrollment, separated by age group, ethnicity, sex and race and describe how they intend to meet those goals, the FDA said. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)
